目的 探讨血必净注射液联合利奈唑胺治疗重症肺炎的临床效果。方法 选取海口市人民医院在2015年4月—2017年4月收治的重症肺炎患者81例，随机分成对照组（40例）和治疗组（41例）。对照组患者静脉滴注利奈唑胺注射液，600 mg/次，2次/d。治疗组患者在对照组的基础上静脉滴注血必净注射液，50 mL加入生理盐水100 mL，2次/d。两组患者均治疗14 d。观察两组患者临床疗效，比较治疗前后两组患者细菌清除率、临床症状和生化指标改善时间及肺功能指标。结果 治疗后，对照组和治疗组临床总有效率分别为77.50%、95.12%，两组比较差异具有统计学意义（P < 0.05）。治疗后，对照组和治疗组细菌清除率分别为55.00%、80.49%；两组比较差异具有统计学意义（P < 0.05）。治疗后，治疗组临床症状和生化指标恢复时间均明显短于对照组，两组比较差异具有统计学意义（P < 0.05）。治疗后，两组患者最大呼气中期流速（MMF）和用力呼气量占用力肺活量比值（FEV₁/FVC）明显升高，呼气峰流速（PEF）明显降低，同组比较差异具有统计学意义（P < 0.05）；且治疗组肺功能各指标改善后情况明显优于对照组，两组比较差异具有统计学意义（P < 0.05）。结论 血必净注射液联合利奈唑胺治疗重症肺炎疗效显著，可有效改善患者肺功能指标，具有一定的临床推广应用价值。

Objective To investigate the clinical effect of Xuebijing Injection combined with linezolid in treatment of severe pneumonia. Methods Patients (81 cases) with severe pneumonia in Haikou People's Hospital from April 2015 to April 2017 were randomly divided into control (40 cases) and treatment (41 cases) groups. Patients in the control group were iv administered with Linezolid Injection, 600 mg/time, twice daily. Patients in the treatment group were iv administered with Xuebijing Injection on the basis of the control group, 50 mL added into normal saline 100 mL, twice daily. Patients in two groups were treated for 14 d. After treatment, the clinical efficacy was evaluated, and the bacterial clearance rate, the improvement time of clinical symptoms and biochemical indexes, the lung function indexes in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 77.50% and 95.12%, respectively, and there were differences between two groups (P < 0.05). After treatment, the bacterial clearance rate in the control and treatment groups were 55.00% and 80.49%, respectively, and there were differences between two groups (P < 0.05). After treatment, the recovery time of clinical symptoms and biochemical indexes in the treatment group was significantly shorter than that in the control group, with significant difference between two groups (P < 0.05). After treatment, the MMF and FEV₁/FVC in two groups were significantly increased, but PEF was significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the lung function indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Xuebijing Injection combined with linezolid has significant effect in treatment of severe pneumonia, can effectively improve the lung function indicators, which has a certain clinical application value.